Immunai stock

Immunai Stock

HealthTech

Looking to sell Immunai stock or options?

Contact us
Founded: 2018Funding to Date: $295M
Visit website

Immunai, a company that developed a technology for the immune system, is intended to offer treatments for auto-immune disorders and oncology. The platform of Immunai merges thorough mapping and reprogramming of the immune system with AI, machine learning, and single-cell biology. This gives fresh insights into the immune system, which allows healthcare researchers to speed up drug development and enhance patient outcomes.

Investors Include:

Meron Capital, Endless Frontier Labs, 8VC, Alexandria Venture Investments, Gefen Capital, Perot Jain, Dexcel Pharma, Piedmont Capital Investments, Talos Ventures, Duquesne Family Office, iAngels, TLV Partners, Schusterman Family Investments, ICON (Palo Alto), R-Squared Ventures, Koch Disruptive Technologies, Gad Allon, Piedmont, Viola Ventures, Catalio Capital Management.

Collective Representative

Looking to sell Immunai Stock or Options?

We have an even better solution: The Collective Exchange Fund

Get in touch and see if we can help you

Loading